RU2312661C2 - Применение циклопамина при лечении псориаза - Google Patents

Применение циклопамина при лечении псориаза Download PDF

Info

Publication number
RU2312661C2
RU2312661C2 RU2004103074/15A RU2004103074A RU2312661C2 RU 2312661 C2 RU2312661 C2 RU 2312661C2 RU 2004103074/15 A RU2004103074/15 A RU 2004103074/15A RU 2004103074 A RU2004103074 A RU 2004103074A RU 2312661 C2 RU2312661 C2 RU 2312661C2
Authority
RU
Russia
Prior art keywords
cyclopamine
skin
psoriatic
shows
lesion
Prior art date
Application number
RU2004103074/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004103074A (ru
Inventor
Шинан ТАШ (TR)
Шинан ТАШ
Октай АВСИ (TR)
Октай АВСИ
Original Assignee
Шинан ТАШ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2312661(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шинан ТАШ filed Critical Шинан ТАШ
Publication of RU2004103074A publication Critical patent/RU2004103074A/ru
Application granted granted Critical
Publication of RU2312661C2 publication Critical patent/RU2312661C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2004103074/15A 2001-07-02 2002-04-19 Применение циклопамина при лечении псориаза RU2312661C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TRPCT/TR01/00027 2001-07-02
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (2)

Publication Number Publication Date
RU2004103074A RU2004103074A (ru) 2005-05-10
RU2312661C2 true RU2312661C2 (ru) 2007-12-20

Family

ID=21619326

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004103074/15A RU2312661C2 (ru) 2001-07-02 2002-04-19 Применение циклопамина при лечении псориаза

Country Status (14)

Country Link
EP (4) EP2862570A1 (OSRAM)
JP (3) JP2004536045A (OSRAM)
KR (1) KR20090125833A (OSRAM)
CN (2) CN1525859B (OSRAM)
AT (2) ATE305300T1 (OSRAM)
AU (1) AU2001272892B8 (OSRAM)
BR (1) BR0117063A (OSRAM)
CA (1) CA2452151C (OSRAM)
DE (2) DE60113733T2 (OSRAM)
DK (2) DK1401438T3 (OSRAM)
ES (3) ES2534400T3 (OSRAM)
PT (1) PT1411938E (OSRAM)
RU (1) RU2312661C2 (OSRAM)
WO (2) WO2002078703A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
JP2010520310A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミンラクタム類似体及びその使用方法
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2000074706A1 (en) * 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
RU2164414C2 (ru) * 1994-06-13 2001-03-27 Биоти Терапиз Корп. Подавление роста опухолевых клеток эктодоменом синдекана-1
WO2001040438A2 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386190C (en) * 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2164414C2 (ru) * 1994-06-13 2001-03-27 Биоти Терапиз Корп. Подавление роста опухолевых клеток эктодоменом синдекана-1
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2000074706A1 (en) * 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
WO2001040438A2 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Реферат Entrez PubMed Tuting T. The immunology of cutaneous DNA immunization. Curr. Opin. Mol. Ther. 1999 Apr; 1(2):216-25. А.РОЙТ и др. Иммунология. - М.: Мир, 2000, с.335-336, 344-345, реферат Entrez PubMed: Bang К. et al. CD4+ CD8+ (thymocyte-like) Т-lymphocytes present in blood and skin from patients with atopic dermatitis suggest immune dysregulation. Br. J. Dermatol. 2001 Jun; 144(6):1140-7. *

Also Published As

Publication number Publication date
CA2452151C (en) 2012-01-03
EP1401438B1 (en) 2005-09-28
EP1401438A1 (en) 2004-03-31
PT1411938E (pt) 2005-11-30
DE60204966T2 (de) 2006-05-18
WO2002078703A1 (en) 2002-10-10
CN1525859B (zh) 2010-05-05
JP2014028834A (ja) 2014-02-13
DK1411938T3 (da) 2005-11-07
DE60113733T2 (de) 2006-06-29
WO2002078703A8 (en) 2003-06-12
DK1401438T3 (da) 2006-02-13
EP2216022A1 (en) 2010-08-11
ES2250434T3 (es) 2006-04-16
EP2862570A1 (en) 2015-04-22
AU2001272892B8 (en) 2006-05-04
ATE299022T1 (de) 2005-07-15
WO2002078704A1 (en) 2002-10-10
DE60204966D1 (de) 2005-08-11
EP1561464A2 (en) 2005-08-10
CN1230169C (zh) 2005-12-07
EP2216022B1 (en) 2015-01-07
CN1522146A (zh) 2004-08-18
EP1561464A3 (en) 2007-04-25
DE60113733D1 (de) 2006-02-09
BR0117063A (pt) 2004-07-27
ES2534400T3 (es) 2015-04-22
ATE305300T1 (de) 2005-10-15
CA2452151A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
KR20090125833A (ko) 2009-12-07
ES2246011T3 (es) 2006-02-01
JP2010132691A (ja) 2010-06-17
JP5424923B2 (ja) 2014-02-26
AU2001272892B2 (en) 2006-03-16
JP2004536045A (ja) 2004-12-02
CN1525859A (zh) 2004-09-01

Similar Documents

Publication Publication Date Title
US9757361B2 (en) Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells
ES2246011T3 (es) Utilizacion de ciclopamina para la preparacion de un medicamento para el tratamiento de la psoriaris.
CA3006143C (en) Methods and compositions for treating dermatological diseases and conditions
HU218936B (hu) Stroncium (II) valamely szervetlen sóját tartalmazó bőriritáció elleni hatású topikális gyógyászati készítmények
US20090149536A1 (en) 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
US10869822B2 (en) Compositions for treatment of dermatological diseases and conditions and methods of use thereof
JP2008540514A (ja) 過剰増殖表皮疾患の治療用組成物及び方法
MXPA00009705A (es) Uso de poliaminas en el tratamiento de sintomas dermatologicos.
RU2146519C1 (ru) Фармацевтическая композиция на основе антагониста вещества p
Strauss et al. Effect of orally administered antibacterial agents on titratable acidity of human sebum
JPH08208508A (ja) 皮膚の赤みの治療におけるサブスタンスｐアンタゴニストの使用
Moglia et al. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses
EP3107536A1 (en) Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory disorders
CN121152629A (zh) 药物组合物
JP3830963B2 (ja) 乾癬治療
EP4640203A1 (en) Skin improvement compositions containing carnitine salicylate (ca-sa) as active ingredient
US20220062308A1 (en) Methods and compositions for treating rosacea
US20180185391A1 (en) Drug Treatment Of Psoriasis And Of Other Skin Disorders Associated With Inhibition Of Differentiation Of Epidermal Cells
KR20260001457A (ko) 안질환의 치료를 위한 국소제로서의 디-이소프로필-포스피노일-알칸

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110420